Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BND-22||BND-22 is an anti-ILT2 monoclonal antibody that blocks ILT2 from interacting with HLA-G, potentially leading to immunosuppressive effects and subsequent anti-tumor activity, including increased macrophage activity and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3266).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04717375||Phase Ib/II||BND-22||Study of BND-22 in Participants With Advanced Solid Tumors||Recruiting||USA||1|